Blood pressure effects of celecoxib or naproxen in patients with JIA

Description:
Juvenile Idiopathic Arthritis (JIA) is the term used to describe a chronic arthritis in children. It involves inflammation of one or more joints usually occurring before the age of 16. JIA is an autoimmune disease meaning that the body’s own immune system begins to attack cells and tissues for an unknown reason. Treatment options vary and may include physical therapy and medications. Celebrex® (celecoxib) is one of the treatment options but not much information is known about the safety and effectiveness of the medication in pediatric patients. This study is evaluating the safety of celecoxib in pediatric patients with JIA.

Medication Under Study:
Celecoxib and Naproxen

Full study title:
A phase 4, 6-week, randomized double-blind, multicenter, active-controlled trial to evaluation the effects of Celecoxib (Celebrex®) or Naproxen on blood pressure in pediatric subjects with juvenile idiopathic arthritis

IRB Study ID:
090608


Who may qualify:

Pediatric patients, 2-18 years,  with juvenile idiopathic arthritis

Who does not qualify:

Patients with other types of arthritis or unable to take the study medications

If you are interested in this study or have questions about your child's eligibility, please contact:

Rebecca D. Considine Research Institute, 330-543-5012

For urgent patient care matters involving a current study patient, please call: 330-920-5774


Lead Principal Investigator:

Photo
Mary Bratovich Toth, MD
Director, Pediatric Rheumatology
Medical Staff, President


Bookmark and Share

iGrow iGrow
Sign up for our parent enewsletter
    Contact Us

    330-543-5012

    E-mail

    find a location
    Find a location Type the first 3-5 letters of a specialty, service or location:
    Or, view: a map, a list of all locations, locations by city or locations near me.
    find a doctor
    Find a doctor Type the first 3-5 letters of the name, location or specialty:
    Or, view a list of all doctors by name, location and specialty.